← 返回

NR4A1 在骨肉瘤病理生理学中的作用:单细胞 RNA 测序数据集的综合生物信息学分析

英文原题:The Role of NR4A1 in the Pathophysiology of Osteosarcoma: A Comprehensive Bioinformatics Analysis of the Single-Cell RNA Sequencing Dataset.

查看英文原题

The Role of NR4A1 in the Pathophysiology of Osteosarcoma: A Comprehensive Bioinformatics Analysis of the Single-Cell RNA Sequencing Dataset.

PubMed 2022/07/28(内容时间) Front Oncol Q2 · IF 3.4(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

骨肉瘤是一种侵袭性人类恶性肿瘤,患者预后仍不理想。研究已证明肿瘤微环境在调节骨肉瘤进展中发挥关键作用;近期研究也显示,单细胞RNA测序(scRNA-seq)对于理解肿瘤异质性及不同肿瘤亚群至关重要。为进一步理解骨肉瘤组织scRNA-seq数据,本研究对GSE152048数据集进行了深入分析,并探讨核受体相关基因在骨肉瘤病理生理过程中的潜在作用。分析在所有骨肉瘤组织中鉴定出11种细胞类型,核受体(NR)分布于各类细胞。

进一步分层分析显示,转移性骨肉瘤中NR主要见于“TIL”和“成骨细胞”群;原发性骨肉瘤中见于“TIL”“肌母细胞”“内皮细胞”和“髓系细胞”;复发性骨肉瘤中见于“软骨母细胞”“成骨细胞”和“周细胞”。转移、原发和复发骨肉瘤不同细胞类型中的NR表达也存在差异。

此外,NR4A2、NR4A1和NR3C1等多个NR基因在不同疾病阶段的多数差异表达基因中呈差异表达。骨肉瘤组织中NR4A1高表达与患者5年总生存期较短显著相关,而NR4A2表达与5年总生存期无显著关联。GSE32981和GSE154540数据验证显示,转移性骨肉瘤NR4A1表达显著高于原发性骨肉瘤;GSE154540还显示,化疗敏感性较差患者的骨肉瘤NR4A1表达高于化疗敏感患者。

进一步分析scRNA-seq数据发现,复发性骨肉瘤中NR4A1高表达成骨细胞比例高于NR4A1低表达成骨细胞。总之,本研究提示NR4A1可能是骨肉瘤进展的重要预后标志物,但仍需进一步验证。

展开英文摘要原文

Osteosarcoma is a kind of aggressive human malignancy, and the prognosis of the patients with osteosarcoma remains low. Studies have demonstrated that the tumor microenvironment plays a key role in regulating osteosarcoma progression. Recent studies have also shown that scRNA-seq plays an essential role in understanding the tumor heterogeneity and distinct subpopulations of tumors.

In order to further understand the scRNA-seq data of osteosarcoma tissues, the present study further analyzed the scRNA-seq dataset (GSE152048) and explored the potential role of nuclear receptor-related genes in the pathophysiology of osteosarcoma. In our analysis, we identified 11 cell types in all the osteosarcoma tissues and nuclear receptors (NRs) were distributed in all types of cells.

Further stratification analysis showed that NRs were mainly detected in "TIL" and "Osteoblastic" of the metastasis osteosarcoma, in "TIL", "Myoblast", "Endothelial", and "Myeloid" of the primary osteosarcoma, and in "Chondroblastic", "Osteoblast", and "Pericyte" of the recurrent osteosarcoma. The NRs were also differentially expressed in different cell types among the metastasis, primary, and recurrent osteosarcoma.

Furthermore, several NRs such as NR4A2, NR4A1, and NR3C1 have been found to be differentially expressed in most types of DEGs among metastasis, primary, and recurrent osteosarcoma. A high expression of NR4A1 in the osteosarcoma tissues was significantly correlated with a shorter 5-year overall survival of patients with osteosarcoma. On the other hand, there was no significant association between NR4A2 expression and the 5-year overall survival of patients with osteosarcoma.

The expression of NR4A1 was significantly higher in the metastasis osteosarcoma tissues than in the primary osteosarcoma tissues as validated from GSE32981 and GSE154540. The expression of NR4A1 was significantly higher in osteosarcoma tissues from patients with poor chemosensitivity than that from patients with good chemosensitivity as validated from GSE154540.

Further analysis of the scRNA-seq data revealed that the percentage of osteoblasts with a high NR4A1 expression was higher in the recurrent osteosarcoma tissues than that with a low NR4A1 expression.

In conclusion, the present study may suggest that NR4A1 may be an important prognostic biomarker for osteosarcoma progression.

However, further validation studies should be performed to confirm our findings.

论文信息

作者
Liu W、Hao Y、Tian X、Jiang J、Qiu Q
单位
Department of Orthopedic, The Affiliated Huaian No. 1 People's Hospital of Nanjing Medical University, Huaian, China.China
期刊
Frontiers in oncology2022
原文标识
PubMed 35965537 · DOI 10.3389/fonc.2022.879288